The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

Author

Díaz-Beyá, Marina

Brunet Mauri, Maria Salut

Nomdedéu, Josep

Pratcorona, Marta

Cordeiro, Anna

Gallardo, David

Escoda, Lourdes

Tormo, Mar

Heras, Inmaculada

Ribera, Jose-Maria

Duarte, Rafael

Llano Queipo, María Paz de

Bargay, Joan

Sampol, Antonia

Nomdedeu, Meritxell

Risueño, Ruth M.

Hoyos Colell, Montserrat

Sierra Gil, Jorge

Monzo, Mariano

Navarro, Alfons

Esteve Reyner, Jordi

Cooperative AML group CETLAM

Universitat Autònoma de Barcelona

Publication date

2015

Abstract

Altres ajuts: SDCSD from School of Medicine, University of Barcelona


Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown.We have examined the expression of the lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) in 241 AML patients. We have correlated HOTAIRM1 expression with a miRNA expression profile. We have also analyzed the prognostic value of HOTAIRM1 expression in 215 intermediate-risk AML (IR-AML) patients.The lowest expression level was observed in acute promyelocytic leukemia (P < 0.001) and the highest in t(6;9) AML (P = 0.005). In 215 IR-AML patients, high HOTAIRM1 expression was independently associated with shorter overall survival (OR:2.04;P = 0.001), shorter leukemia-free survival (OR:2.56; P < 0.001) and a higher cumulative incidence of relapse (OR:1.67; P = 0.046). Moreover, HOTAIRM1 maintained its independent prognostic value within the favorable molecular subgroup (OR: 3.43; P = 0.009). Interestingly, HOTAIRM1 was overexpressed in NPM1-mutated AML (P < 0.001) and within this group retained its prognostic value (OR: 2.21; P = 0.01). Moreover, HOTAIRM1 expression was associated with a specific 33-microRNA signature that included miR-196b (P < 0.001). miR-196b is located in the HOX genomic region and has previously been reported to have an independent prognostic value in AML. miR-196b and HOTAIRM1 in combination as a prognostic factor can classify patients as high-, intermediate-, or low-risk (5-year OS: 24% vs 42% vs 70%; P = 0.004).Determination of HOTAIRM1 level at diagnosis provided relevant prognostic information in IR-AML and allowed refinement of risk stratification based on common molecular markers. The prognostic information provided by HOTAIRM1 was strengthened when combined with miR-196b expression. Furthermore, HOTAIRM1 correlated with a 33-miRNA signature

Document Type

Article

Language

English

Subjects and keywords

Leucèmia; Genètica; AML; HOTAIRM; HOX; Lincrna; Lncrna

Publisher

 

Related items

Instituto de Salud Carlos III CM13/00205

Instituto de Salud Carlos III PI13/00999

Instituto de Salud Carlos III RETICS/RD12/0036/0010

Oncotarget ; Vol. 6 Núm. 31 (October 2015)

Rights

open access

Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.

https://rightsstatements.org/vocab/InC/1.0/

This item appears in the following Collection(s)